小柯机器人

SARS-CoV-2 mRNA疫苗已进入三期临床试验
2020-08-07 13:48

近日,美国国立卫生研究院Barney S. Graham等研究人员通过原型病原体实现SARS-CoV-2 mRNA疫苗的设计。相关论文于2020年8月5日在线发表在《自然》杂志上。

研究人员利用原子级结构指导了融合前稳定突变的应用,这些突变改善了β冠状病毒刺突蛋白的表达和免疫原性。使用这种免疫原设计,SARS-CoV-2序列的破译促进了融合前稳定的SARS-CoV-2突刺三聚体mRNA疫苗(mRNA-1273)的生产。
 
研究人员发现,mRNA-1273可以诱导对野生型(D614)和D614G突变体SARS-CoV-2的有效中和抗体反应以及CD8 T细胞反应,并能防止小鼠肺和鼻中的SARS-CoV-2感染,而且没有产生免疫病理。mRNA-1273当前处于3期功效评估中。
 
附:英文原文

Title: SARS-CoV-2 mRNA vaccine design enabled by prototype pathogen preparedness

Author: Kizzmekia S. Corbett, Darin K. Edwards, Sarah R. Leist, Olubukola M. Abiona, Seyhan Boyoglu-Barnum, Rebecca A. Gillespie, Sunny Himansu, Alexandra Schfer, Cynthia T. Ziwawo, Anthony T. DiPiazza, Kenneth H. Dinnon, Sayda M. Elbashir, Christine A. Shaw, Angela Woods, Ethan J. Fritch, David R. Martinez, Kevin W. Bock, Mahnaz Minai, Bianca M. Nagata, Geoffrey B. Hutchinson, Kai Wu, Carole Henry, Kapil Bahi, Dario Garcia-Dominguez, LingZhi Ma, Isabella Renzi, Wing-Pui Kong, Stephen D. Schmidt, Lingshu Wang, Yi Zhang, Emily Phung, Lauren A. Chang, Rebecca J. Loomis, Nedim Emil Altaras, Elisabeth Narayanan, Mihir Metkar, Vlad Presnyak, Cuiping Liu, Mark K. Louder, Wei Shi, Kwanyee Leung, Eun Sung Yang, Ande West, Kendra L. Gully, Laura J. Stevens, Nianshuang Wang, Daniel Wrapp, Nicole A. Doria-Rose, Guillaume Stewart-Jones, Hamilton Bennett, Gabriela S. Alvarado, Martha C. Nason, Tracy J. Ruckwardt, Jason S. McLellan, Mark R. Denison, James D. Chappell, Ian N. Moore, Kaitlyn M. Morabito, John R. Mascola, Ralph S. Baric, Andrea Carfi, Barney S. Graham

Issue&Volume: 2020-08-05

Abstract: A vaccine for severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) is needed to control the global coronavirus infectious disease (COVID-19) public health crisis. Atomic-level structures directed the application of prefusion-stabilizing mutations that improved the expression and immunogenicity of betacoronavirus spike proteins1. Using this established immunogen design, the release of SARS-CoV-2 sequences triggered immediate rapid manufacturing of an mRNA vaccine expressing the prefusion-stabilized SARS-CoV-2 spike trimer (mRNA-1273). Here we show that mRNA-1273 induces both potent neutralizing antibody responses to wild-type (D614) and D614G mutant2 SARS-CoV-2 and CD8 T cell responses, and protects against SARS-CoV-2 infection in the lungs and noses of mice without evidence of immunopathology. mRNA-1273 is currently in Phase 3 efficacy evaluation.

DOI: 10.1038/s41586-020-2622-0

Source: https://www.nature.com/articles/s41586-020-2622-0

Nature:《自然》,创刊于1869年。隶属于施普林格·自然出版集团,最新IF:43.07
官方网址:http://www.nature.com/
投稿链接:http://www.nature.com/authors/submit_manuscript.html


本期文章:《自然》:Online/在线发表

分享到:

0